|
18 Companies |
|
19 Products |
|
19 Products |
|
22 Mechanisms of Action |
|
0 Trials |
|
61 News |
|
| «12 |
- valsartan / Generic mfg.
Trial completion: A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy (clinicaltrials.gov) - Aug 26, 2013
P4, N=75, Completed, Sponsor: Guangdong General Hospital
Active, not recruiting --> Completed
- | Tekturna (aliskiren) / PDL
Enrollment change, Combination therapy: Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease (clinicaltrials.gov) - Jul 30, 2013
P4, N=46, Completed, Sponsor: Columbia University
Active, not recruiting --> Completed N=120 --> 46
- | Tekturna (aliskiren) / PDL
Trial completion, Combination therapy: Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease (clinicaltrials.gov) - Jul 30, 2013
P4, N=46, Completed, Sponsor: Columbia University
N=120 --> 46 Active, not recruiting --> Completed
- Trial completion: Development of a Metabolic Assessment Tool for Chronic Kidney Disease (clinicaltrials.gov) - Apr 22, 2013
P=N/A, N=12, Completed, Sponsor: Angela Zivkovic, PhD
Active, not recruiting --> Completed Not yet recruiting --> Completed
- Enrollment open: NIDOCIGA: IgA Nephropathy, Lymphocyte Homing and IgA Class Switch (clinicaltrials.gov) - Mar 25, 2013
P=N/A, N=72, Recruiting, Sponsor: University Hospital, Limoges
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- | mycophenolate mofetil / Generic mfg.
Trial completion: Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (clinicaltrials.gov) - Jan 27, 2013
P3, N=184, Completed, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
Not yet recruiting --> Recruiting Recruiting --> Completed
- Tekturna (aliskiren) / PDL
Enrollment change, IO biomarker: Aliskiren for Immunoglobulin A (IgA) Nephropathy (clinicaltrials.gov) - Dec 2, 2012
P3, N=22, Completed, Sponsor: Chinese University of Hong Kong
Recruiting --> Completed N=57 --> 22
- Tekturna (aliskiren) / PDL
Trial completion, IO biomarker: Aliskiren for Immunoglobulin A (IgA) Nephropathy (clinicaltrials.gov) - Dec 2, 2012
P3, N=22, Completed, Sponsor: Chinese University of Hong Kong
N=57 --> 22 Recruiting --> Completed
- ||||| Tarpeyo (budesonide) / Calliditas, Stada
New P2 trial: NEFIGAN: The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease (clinicaltrials.gov) - Nov 28, 2012
P2, N=90, Active, not recruiting, Sponsor: Pharmalink AB
- ||||||| omega-3 ethylester concentrate / Generic mfg.
Trial completion: IgAN: Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy (clinicaltrials.gov) - Sep 24, 2012
P3, N=152, Completed, Sponsor: Kuhnil Pharmaceutical Co., Ltd.
Recruiting --> Completed Active, not recruiting --> Completed
- | H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
Trial completion: Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) (clinicaltrials.gov) - Jul 31, 2012
P4, N=15, Completed, Sponsor: Columbia University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- prednisone / Generic mfg.
Trial completion: The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy (clinicaltrials.gov) - Jul 8, 2012
P=N/A, N=30, Completed, Sponsor: Nanjing University School of Medicine
Active, not recruiting --> Completed Recruiting --> Completed
- | cyclophosphamide / Generic mfg.
Enrollment closed: STOP-IgAN: Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy (clinicaltrials.gov) - Apr 22, 2012
P3, N=148, Active, not recruiting, Sponsor: RWTH Aachen University
Recruiting --> Completed Recruiting --> Active, not recruiting
- | tacrolimus intravenous / Generic mfg.
Trial completion: A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients (clinicaltrials.gov) - Oct 6, 2011
P2, N=40, Completed, Sponsor: Astellas Pharma Inc
Recruiting --> Active, not recruiting Recruiting --> Completed
- Trial withdrawal: Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis (clinicaltrials.gov) - Aug 7, 2011
P=N/A, N=90, Withdrawn, Sponsor: Nanjing University School of Medicine
Recruiting --> Completed Recruiting --> Withdrawn